Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2015-01-22 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Collaboration Agreement with Simbec-Orion
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and 'FOR IMMEDIATE RELEASE', indicating it is a regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). The content details a 'Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study' between ImmuPharma PLC and Simbec-Orion. This is a significant corporate event announcement regarding a clinical trial partnership and associated financing/investment structure (Simbec-Orion reinvesting fees as shares). While it discusses clinical trials (which might suggest IR or LTR), the primary function is announcing a major business development and partnership, which is typically classified as a general regulatory filing or announcement when it doesn't fit a more specific category like M&A (TAR) or Director's Dealing (DIRS). Since it is a broad, immediate corporate update distributed via RNS, and it is not a full financial report (10-K, IR) or a specific management/remuneration disclosure, the most appropriate general category is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is the substance of the news, not just an announcement that a report is available.
2015-01-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly marked with an 'RNS Number' and contains the header 'FOR IMMEDIATE RELEASE'. The content details a change in shareholding by a major investor (Odey Asset Management) increasing their stake to 3.87% following a recent fund-raising event. This type of announcement, concerning changes in significant share ownership, directly maps to the Major Shareholding Notification category. Although it is an RNS announcement, the specific nature of the content (major shareholder change) makes 'MRQ' (Major Shareholding Notification) a more precise classification than the general 'RNS' fallback.
2014-10-30 English
Holding(s) in Company
Regulatory Filings Classification · 1% confidence The document is clearly identified as an 'RNS Number' announcement from Immupharma PLC, dated October 28, 2014. The title is 'NOTIFICATION OF AVIVA'S MAJOR INTEREST IN SHARES'. The content details a change in shareholding percentage (from below 4% to 9.19%) by Aviva plc, referencing a TR-1 form, which is the standard regulatory form for notifying major interests in shares. This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is an RNS announcement, the specific content is a major shareholding change, making MRQ the most precise classification over the general RNS fallback.
2014-10-28 English
Additional Listing - Conditional Placing
Share Issue/Capital Change Classification · 1% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the London Stock Exchange news service. The content details a conditional fundraising effort (£3.4 million) through a placing of new ordinary shares at a specific price, which directly relates to capital structure changes and financing activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it is an RNS announcement, the core subject matter is a specific financial event (fundraising/share issue) rather than a general regulatory update, making CAP a more precise classification than the fallback RNS.
2014-10-21 English
ImmuPharma awarded EUR400,000 Grant
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '20 October 2014'. It is a short press release format announcing that ImmuPharma PLC has been awarded a €400,000 grant for research. The text concludes with the explicit statement: 'This information is provided by RNS The company news service from the London Stock Exchange'. This structure strongly indicates a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action announcement (like DIV, CAP, DIRS), the most appropriate classification is the general regulatory filing category.
2014-10-20 English
Half Yearly Report
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for ImmuPharma PLC for the six months ended 30 June 2014. It contains comprehensive financial statements (Consolidated Income Statement, Statement of Financial Position, etc.) and an independent review report. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2014
2014-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.